CPI-0209

Phase 1Small molecule

LLan Coffman

CPI-0209 is one of 8 small molecule programs targeting Recurrent Ovarian Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Ovarian CancerRecruiting

Recurrent Ovarian CancerPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Recurrent Ovarian Cancer

#DrugCompanyPhaseTrials

Elahere

IImmunogenics, LLC

Phase 2

1 2

Paraplatin

AAvyxa

Phase 1

1 3

Libtayo

Regeneron

Preclinical

1 4

Lubricating Eye Drop

AbbVie

Phase 2

1 5

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

1 6

Actemra

CCelltrion

Preclinical

1 7

Ubamatamab

Regeneron

Preclinical

1 8

CPI-0209

LLan Coffman

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Recurrent Ovarian Cancer

NCT05942300

Clinical

Trials by Indication[1]

Recurrent Ovarian Cancer1 trial

Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Recruiting·LLan Coffman·Phase 1·NCT05942300·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CPI-0209. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CPI-0209 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CPI-0209. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lan Coffman company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: LLan Coffman

CPI-0209

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Recurrent Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News